TCG Crossover Management »

Immunovant shares owned by TCG Crossover Management

Quarter-by-quarter ownership of Immunovant (IMVT) shares owned by TCG Crossover Management from 13F filings

Historical chart of TCG Crossover Management investment in Immunovant

Tip: Access up to 7 years of quarterly data

All positions including Immunovant held by TCG Crossover Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Immunovant by TCG Crossover Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $42M 1.7M 25.42
2023-09-30 $13M 335k 38.39
2023-06-30 $12M 655k 18.97
2023-03-31 $10M 655k 15.51
2022-12-31 $15M 855k 17.75

More positions owned by TCG Crossover Management

Abivax Sa American Depositary Shares Adrs (ABVX)
Cogent Biosciences Comm (COGT)
Cg Oncology Comm (CGON)
Tango Therapeutics Comm (TNGX)
Centessa Pharmaceuticals Adrs (CNTA)
Dyne Therapeutics Comm (DYN)
Rapt Therapeutics Comm (RAPT)
Tyra Biosciences Comm (TYRA)
Amylyx Pharmaceuticals Comm (AMLX)
Savara Comm (SVRA)
Monte Rosa Therapeutics Comm (GLUE)
Ocular Therapeutix Comm (OCUL)
Dianthus Therapeutics Comm (DNTH)
Eyepoint Pharmaceuticals Comm (EYPT)
Structure Therapeutics Adrs (GPCR)

View all positions for TCG Crossover Management

Top funds holding Immunovant

FMR
Deep Track Capital
Vanguard Group
BlackRock
Armistice Capital
Baker Bros. Advisors
T. Rowe Price Investment Management
State Street Corporation
Rtw Investments
Two Seas Capital
Alpine Partners VI
ADAR1 Capital Management
Point72 Asset Management
Woodline Partners
Geode Capital Management

View all funds holding Immunovant